Vaccination with an adeno-associated virus gene transfer vector containing the sequence of an antinicotine antibody prevents nicotine from entering the brain and has potential as a treatment for nicotine addiction, report investigators at Weill Cornell Medical College, in New York City (Hick MJ et al. Sci Transl Med. 2012;4:140ra87).
In nicotine-dependent mice treated with the vector, called AAVantiNic, blood concentrations of the anti-nicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. Also, a single dose of the therapy generated a high antibody titer at 4 weeks, which remained high at 18 weeks.
Hampton T. Vaccine for Smokers? JAMA. 2012;308(5):444. doi:10.1001/jama.2012.9054
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: